Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia

• Status: Completed
• Trial end date: 2017-07-21
• Target enrollment: 0
• Participant gender: All

Summary

The objectives of this 12-week study are to evaluate the efficacy, safety, and tolerability of AVP-786 as an adjunctive treatment compared with placebo in patients with residual schizophrenia.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Avanir Pharmaceuticals
• Treatments: Dextromethorphan

Criteria

Inclusion Criteria:

• Patients who meet DSM-IV-TR diagnostic criteria for schizophrenia using the M.I.N.I. version 6.0.

• Patients must meet PANSS criteria

• Patients currently receiving atypical antipsychotics are eligible provided they are on a stable dose

Exclusion Criteria:

• Patients with current major depressive disorder (MDD)

• Patients with extrapyramidal syndrome secondary to their ongoing antipsychotic medication

• Patients currently using anticholinergic medications

• Recent in-patient hospitalization